Study of Meningitis B vaccination schedule on the childhood in Zaragoza

• Published in: Vacunas (Barcelona. Internet. English ed.) 2022-09, Vol.23 (3), p.159-164
• Main Authors: Genzor Ríos, Cristina, Vázquez Sánzchez, María, Molina Herranz, David, Fariña Jara, María Violeta, López Campos, Mónica, Llamas Agundez, Enrique, Viñas Viamonte, María Pilar, Fernández Lozano, Carlos
• Format: Article
• Language: English
• Subjects: Errores de Medicación; Medication errors; Meningitis; Neisseria meningitidis; Pediatria; Pediatrics; Serogroup B; Serogrupo B; Vaccination; Vaccines; Vacunación; Vacunas
• ISSN: 2445-1460; 2445-1460
• DOI: 10.1016/j.vacune.2022.10.003

Meningococcal disease caused by Neisseria meningitidis is a life-threatening disease, with the highest incidence rates in children under 5 years of age. Since 2015, a vaccine against serogroup B, the most prevalent in Europe, has been available in Spain. The objective of the study was to analyse the vaccination of children with Meningitis B in Zaragoza. A descriptive observational study was carried out with 11 776 of 13 Health Centres of Sector I of Zaragoza, aged 0 months to 15 years, with a history of Meningitis B vaccination between January 2015 and December 2019. It was determined sex, date of birth, date and age of primary vaccination, health centre, and vaccination schedule. A descriptive analysis and hypothesis testing was carried out to analyse the results. 50.4% of those vaccinated were between 2 and 9 years old. In 2016, children under 3 months of age represented 7.2% of the total vaccinated, increasing in 2019 to 50.9%. 83.8% of the children were well vaccinated, with a mean age of 5.5 years. Interval errors were more common in the 12–23-month group (55.9%). There were no differences between both sexes in relation to the pattern received. The percentage of well vaccinated is high. The percentage of interval errors in the 12–23-month group, with a more complex vaccination schedule, is of concern. It is important to minimise errors in vaccination to achieve better protection rates. La enfermedad meningocócica provocada por Neisseria Meningitidis es una enfermedad potencialmente mortal, con las mayores tasas de incidencia en menores de 5 años. Desde 2015 se dispone en España de una vacuna contra el serogrupo B, el más predominante en Europa. El objetivo del estudio fue analizar la vacunación de Meningitis B a niños en Zaragoza. Se realizó un estudio observacional descriptivo con 11776 niños de 13 Centros de Salud del Sector I de Zaragoza, con edades de 0 meses a 15 años, con antecedente de vacunación de Meningitis B entre enero de 2015 y diciembre de 2019. Se determinó el sexo, fecha de nacimiento, fecha y edad de primovacunación, centro de salud y pauta vacunal. Se llevó a cabo un análisis descriptivo y contraste de hipótesis para analizar los resultados. El 50.4% de los vacunados tenía entre 2 y 9 años. En 2016, los menores de 3 meses representaban un 7.2% del total de vacunados, aumentando en 2019 a 50.9%. El 83.8% de los niños fueron bien vacunados, con edad media de 5.5 años. Los errores de intervalo fueron más comunes en el grupo de 12 a 23 m